Conatus Pharmaceuticals IPO Research Information

Conatus Pharmaceuticals IPO Advisory

Share this IPO Profile:

Smart Search

For IPO Boutique's "scale of 1 to 5" BUY rating on Conatus Pharmaceuticals, and our comprehensive analysis, click "Buy Market Research".

Company	Symbol	Price Range	Issue Price	Open	Shares	Trade Date
Conatus Pharmaceuticals	CNAT - NASDAQ	$10.00-$12.00	$11.00	$11.00	6 million	7/25/2013
Underwriter(s): Stifel Nicolaus Weisel, Piper Jaffray
Co-Manager(s): JMP Securities, SunTrust Robinson Humphrey
Industry: Health Care
Filing(s): Filed 2013-06-13

Conatus Pharmaceuticals Quote & Chart - Click for current quote - CNAT

About Conatus Pharmaceuticals (adapted from Conatus Pharmaceuticals prospectus):
They are a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease.

This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.

IPO Boutique aggregates information on public companies and private companies, such as "CNAT" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.